Search Results

You are looking at 41 - 50 of 1,067 items for :

  • "community" x
  • Refine by Access: All x
Clear All
Full access

Adjuvant Chemotherapy Regimens for Breast Cancer

Data adapted from Bergstrom et al. 1 Data based on reporting from 750 community oncology practices in the United States to McKesson Specialty Care Solutions. Adjuvant chemotherapy for breast cancer has evolved over several decades

Full access

BPI22-015: Analysis of NCCN-Preferred Treatment Regimen Ordering via an EHR-Embedded Decision Support Tool in a Community Oncology Practice

Jonas M Congelli, Rebecca Maniago, Stephanie Jou, Janet Donegan, and Ivy Altomare

documentation of NCCN Guideline concordant and NCCN preferred treatment regimens. We assessed patterns of concordant, preferred and non-preferred treatment regimen ordering at one large multi-site community practice. Methods : We reviewed all treatment orders

Full access

HSR22-167: Burden of Myelosuppression Among Patients With Extensive-Stage Small Cell Lung Cancer Treated With Chemotherapy in a Community Oncology Setting

Jeffrey Scott, Dean Slack, Lindsay Gingras, Marc Chioda, and Huan Huang

study aimed to assess the prevalence of HAEs and associated health care resource utilization among patients receiving chemotherapy for ES-SCLC in the community oncology setting. Methods : Adult patients with ES-SCLC included in the Integra Connect

Full access

HSR21-047: Tumor Lysis Syndrome Risk Analysis in a US Community Oncology Setting: A Retrospective Observational Study in Integra Connect Network

Kaustav Chatterjee, Edward Drea, Robert Smith, Mei Xue, Hunter Lambert, Jeffrey Scott, Sorena Nadaf, Simon Blanc, Prateesh Varughese, and John Verniero

following chemotherapy [1] . However, no real-world data has been published that quantifies TLS risk factors by cancer type. Methods: The Integra database of 17 community oncology accounts was queried for patients ≥18 years of age having a TLS ICD10 code

Full access

EPR22-113: Awareness, Utilization, and NCCN Guideline-Adherence to Breast Cancer Risk Management Behavior Among a Community-Based Sample of High-Risk Women

Rachel J Meadows, Anna Muraveva, Christina Bijou, Kate Shane-Carson, Coralia Balasca, Celia E Wills, Lisa D Yee, Electra D Paskett, and Tasleem J Padamsee

, community-based sample. Methods : This study uses data (collected Oct 2018–Aug 2019) from a survey that included measures of risk-management behavior, potential correlates, and information necessary to determine lifetime BC risk. Eligible participants were

Full access

HSR23-111: Real-World EGFR Testing in Patients With Surgically Resected Stage I-III Non–Small Cell Lung Cancer (NSCLC) in US Community Oncology Practices

Anne Shah, Jon Apple, Joanne Willey, Michael Ayars, Daniel Simmons, Dana Nickleach, Ganiat Mumuney, Manish Patel, and Kristen Brunskill

25 Nov 2020 to encourage testing for EGFR mutations in eligible patients with resectable NSCLC. This study evaluated real-world testing for EGFR, including the impact of guideline changes (before vs after 25 Nov 2020) on testing in the US community

Full access

BPI22-010: Applying FRAME to Code Modifications to a Community-Based Educational Intervention and Lung Cancer Screening Protocols Amidst the Covid-19 Pandemic

Sydney Beache, Aimee James, Graham Colditz, and Courtney Harriss

Background : While lung cancer is a leading cause of death in the U.S., annual screening rates with low-dose Computed Tomography (LDCT) among eligible candidates remain low at 12.7%. The WUSTL research group began a community intervention to

Full access

HSR24-156: Treatment Patterns and Blood Count Control in 10,112 Patients With Polycythemia Vera Managed at Community Practices in the United States

Jingbo Yu, Anupama Vasudevan, Harvey Katzen, and Evan Braunstein

low-risk and all high-risk patients (pts). This study describes cytoreductive tx and blood count control in pts with PV in large networks of US community oncology practices. Methods: This retrospective study included adults with a new PV diagnosis

Full access

QIM23-132: Do EHR-Embedded Clinical Decision Support Tools Reduce Variation in Care? A Pre and Post-Implementation Comparison of Regimen Ordering Variation at a Multi-Site Community Cancer Clinic

Jonas M. Congelli, Heather Lewin, Gregory Calip, Marcello Ricottone, Shawn Huda, Taylor Dias-Foundas, and Rebecca Maniago

community cancer clinic to determine if variation in regimens ordered was impacted by implementing the CDS tool. Methods: This study used the nationwide EHR-derived de-identified Flatiron Health database to analyze treatment regimens ordered for Breast

Full access

HSR24-161: Biomarker Testing, Surgical Outcomes, and Adjuvant Therapy Rates Among Patients With Resected Non–Small Cell Lung Cancer (NSCLC) in the Community Setting in the United States (US), 2019–2023

Xiaohan Hu, Yu-Han Kao, Ashwini Arunachalam, Diana Chirovsky, Yiru Wang, Chenan Zhang, Kaitlyn Kane, and Ayman Samkari

database integrating patient care information from US community practices. Patients in a clinical trial, who had received neoadjuvant therapy, or with other primary cancer before the NSCLC diagnosis were excluded. We evaluated patient characteristics